Changing cellular instructions
Gene therapy delivers genetic material or modifies cells to produce a therapeutic effect. In cancer, this can include delivery of a tumor-suppressor gene or engineering immune cells. Genetic testing only reads information; it is not itself gene therapy. A TP53 alteration on a report does not automatically make a p53 gene-delivery product suitable.
Gene delivery, cell engineering and testing are different
A gene can be delivered directly into tissue, or cells can be modified outside the body and then infused. The vector, intended gene function and route determine the clinical problem being addressed. Reading a mutation does not repair it, and a gene-delivery product does not necessarily correct every cancer cell in the body.
Evaluating a proposed use
Confirm the exact product and current local label, the tumor site, route of delivery, combination partner and evidence for the proposed setting. Reports of use in another cancer are not proof of an approved indication or superiority to modern standard care. Local injection also requires an accessible lesion and an assessment of bleeding and procedural risk.
Ask what the new component adds
If a study combined a gene product with radiotherapy, its results concern that combination in the studied cancer. They do not show that the gene product alone can replace radiation. When evaluating an offer, compare it with a contemporary standard option and ask whether evidence measures tumor response, recurrence or survival.
Global treatment frontiers
Direct gene delivery and engineered immune cells represent different routes within cancer gene therapy. Gendicine, developed in China, is an early example of local p53 gene delivery studied with radiotherapy in head and neck cancer. Its historical importance should be distinguished from evidence for newer vectors and different diseases.
A 2026 Phase III report of aglatimagene besadenovec with valacyclovir and radiotherapy in localized prostate cancer illustrates the continuing international development of intratumoral gene delivery. It reported a disease-free-survival benefit, but a positive trial is separate from marketing approval. Neither result establishes a universal gene therapy for cancer.
A positive trial and an approved product answer different questions
CAN-2409 evaluated intratumoral aglatimagene with valacyclovir and radiotherapy. Its disease-free survival finding highlights a combination strategy for localized prostate cancer. For patients exploring this approach, the next steps are to confirm the current development status and whether an appropriate study or approved route is available.
Safety depends on the platform
Fever, inflammatory reactions and local procedural effects may occur. Viral vectors, doses and delivery routes differ; long-term monitoring requirements are platform-specific. Ask what is known from the exact product rather than accepting reassurance based on the broad term “gene therapy.”
Questions before traveling
Will the treatment supplement or replace a standard option? What evidence supports that choice? Which hospital will provide the procedure and emergency care? Request a written treatment plan and product identity. Manufacturing claims, patents and early laboratory findings should not be presented as clinical benefit.
Request a treatment plan that can be checked
- Product and vector name, route, number of procedures and combination treatment.
- Evidence for the same cancer stage, with the relevant comparator.
- Current authorization for this use and consent for any investigational component.
- Monitoring, vector-specific precautions and care if the disease worsens.
Treatment costs & individual consultation
Cancer gene therapy costs require an individual assessment of the specific product, delivery method and combination treatment. Local administration, associated radiotherapy or other medicines, monitoring and follow-up all affect the overall cost.
Contact us for an individual cost consultation. Once treatment suitability and an available pathway have been established, we can help clarify the relevant medical costs. Travel and accommodation are separate.
Evidence & sources
Prepared by Chirona’s content team from the sources below. This guide supports a discussion with your treating team; it does not determine an individual treatment plan.